Medicaid now covers genetic testing for children with rare diseases

What it does

This bill amends Medicaid to require coverage of whole genome and whole exome sequencing (genetic tests that read a child's entire DNA or protein-coding regions) for children suspected of having genetic disorders, rare diseases, or conditions of unknown origin. The bill mandates that states pay for these tests as a first-tier diagnostic tool when ordered by a physician, requires separate payment rather than bundling with other services, and directs HHS to conduct outreach and publish data on implementation and outcomes.

Why we flagged it

The bill's core mechanism is a straightforward expansion of Medicaid's covered services to include whole genome and exome sequencing for children with suspected genetic or rare diseases. It is a public-health measure that broadens diagnostic access rather than a tax provision, deregulation, or appropriation.

What the text implies

• Genetic testing expansion may increase downstream healthcare costs if sequencing identifies conditions requiring expensive treatments; bill does not address cost containment or treatment coverage limits.
• Separate payment mandate may incentivize genetic testing volume; states will bear costs, creating potential budget pressure on state Medicaid programs.
• Outreach and education provisions may benefit genetic testing companies and laboratories through increased demand, though benefit is indirect and contingent on clinical uptake.
• Prior authorization barriers are flagged for study but not eliminated by the bill; implementation depends on state plan amendments and CMS guidance, creating uncertainty in actual access.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Low-income children and families gain access to advanced genetic diagnostic testing that can identify rare diseases and genetic disorders, enabling earlier intervention and treatment. The bill removes a coverage barrier and mandates transparent, separate payment to reduce claim denials from bundling or prior authorization delays.

Who stands to gain

• genetic testing laboratories and sequencing service providers
• pediatric genetic specialists and genetic counselors (through increased referrals)
• children's hospitals and health systems offering genetic services

Named in the bill

Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS), Medicaid program (Title XIX, Social Security Act), Comptroller General of the United States, pediatricians, pediatric rare disease specialists, genetic counselors, children's hospitals, Medicaid managed care organizations, rare disease patient organizations

Where it stands

27 cosponsors: 14 Democrats, 13 Republicans.

• Jan 15, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jan 15, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

11 lobbying clients named this bill on 13 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $3,016,008 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 92% of bills with at least one filing.

Scott Peters, the sponsor, reported $1,197,250 in PAC receipts in the 2026 cycle.

• Astrazeneca Pharmaceuticals Lp — $1,680,000 on 1 filing
• College of American Pathologists — $486,008 on 2 filings
• Illumina, Inc. — $300,000 on 1 filing
• Soleno Therapeutics, Inc. — $150,000 on 2 filings
• Nemours Foundation - a Florida Not-for-profit Corporation — $140,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.